降低对抗氧化剂组合疗法反应的动脉刚度指数 (SI)
Laurence Guy Howes1,2,3, Tanya Unni4, Ameer Hamza4
1Department of Cardiology, Gold Coast University Hospital, Gold Coast 4215, Australia.
Journal of clinical medicine
|November 14, 2023
概括
一种新的抗氧化剂组合在一组多样化的志愿者中显著降低了动脉硬度. 这一发现表明了管理心血管健康和预防动脉硬化的一种强有力的新方法.
科学领域:
- 心血管研究研究心血管研究
- 营养科学 营养科学
- 氧化压力生物学 氧化压力生物学
背景情况:
- 之前的研究表明,常见的抗氧化剂 (维生素E,C,A,β-胡卜素) 对动脉硬度的影响很弱,脉冲波速度 (PWV) 的效果大小约为-0.20.
- 在老鼠身上进行的研究表明,含硫的抗氧化剂 (胺,l-氨酸) 与甲酸相结合,可以提供强大的抗氧化应激保护.
- 这些特定抗氧化剂组合对人类动脉硬性的影响以前没有被研究过.
研究的目的:
- 为了评估2周治疗使用含硫抗氧化剂 (氨酸,氨酸,氨酸) 加上 Askorbic 酸对动脉硬度的组合的效果.
- 为了评估刚度指数 (SI) 的变化,一个经过验证的测量方法与PWV有很强的相关性.
- 为了将治疗效果的大小与之前报告的抗氧化剂研究进行比较.
主要方法:
- 这是一项随机对照试验,涉及78名多元志愿者.
- 干预组接受了为期2周的治疗,其中包括囊素,胺,铁素和 Askorbic 酸.
- 使用脉冲记录仪测量动脉硬度,以确定硬度指数 (SI).
主要成果:
- 与安慰剂相比,抗氧化剂联合治疗导致SI显著减少-1.7m/s.
- 这代表SI减少了19%,玻璃效应尺寸非常大,为1.4.
- 观察到的治疗效果大大强于之前对常见抗氧化剂的研究报告的效果.
结论:
- 含硫抗氧化剂 (氨酸,氨酸,氨酸) 与甲酸的组合显示出在降低动脉硬方面具有强效.
- 观察到的SI的减少表明这种抗氧化剂组合在控制或预防心血管疾病方面的潜力.
- 需要进一步的研究来证实这些抗氧化剂组合在临床环境中的治疗价值.
相关概念视频
01:26Atherosclerosis III: Management
11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
10
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
10
01:23Atherosclerosis IV: Nursing Management
17
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
17
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
750
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
750